Healthcare / Medical DevicesStockholm
$8.76
-0.08 (-0.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $13.1M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$125M
P/E
35.0x
↑EV/EBITDA
6.5x
↓ROE
6.7%
↑Gross Margin
40.7%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.5%
FCF CAGR
—
FCF margin
10.0%
FCF / Net income
2.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $130.8M · net income $5.0M · FCF $13.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $130.8M | $130.8M | $156.8M | $163.0M | $125.0M |
| Net Income | $5.0M | $5.0M | $11.2M | $2.6M | $1.9M |
| EBITDA | $13.8M | $13.8M | $22.0M | $12.6M | $9.6M |
| EPS | 0.35 | 0.35 | 0.85 | 0.19 | 0.14 |
| Gross Margin | 40.7% | 40.7% | 39.9% | 35.5% | 40.3% |
| Operating Margin | 4.8% | 4.8% | 8.7% | 2.9% | 2.5% |
| Net Margin | 3.8% | 3.8% | 7.1% | 1.6% | 1.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.08 | 0.55 |
| Current Ratio | 3.12 | 3.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.1M | $13.1M | $12.1M | $16.6M | $-4.3M |
| Returns | |||||
| ROE | 6.7% | 6.7% | 18.8% | 5.3% | 4.1% |
| Valuation | |||||
| P/E | 35.04 | 35.04 | 12.82 | 41.84 | 57.00 |
| EV/EBITDA | 6.54 | 6.54 | 5.93 | 8.22 | 12.54 |
| P/B | 1.68 | 1.68 | 2.42 | 2.15 | 2.29 |
| Growth & Yield | |||||
| Revenue Growth | -16.6% | -16.6% | -3.8% | 30.4% | — |
| EPS Growth | -58.8% | -58.8% | 347.4% | 35.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
30.5%
EPS terminal req.
$0.78
Spread vs growth
-89.3%
5Y implied EPS CAGR
21.9%
EPS terminal req.
$0.94
Spread vs growth
-80.7%
10Y implied EPS CAGR
15.8%
EPS terminal req.
$1.51
Spread vs growth
-74.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.6%
Start / end P/E
11.5x → 25.0x
EPS bridge
0.85 → 0.35
Residual
-68.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.